DE60328772D1 - Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen - Google Patents

Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen

Info

Publication number
DE60328772D1
DE60328772D1 DE60328772T DE60328772T DE60328772D1 DE 60328772 D1 DE60328772 D1 DE 60328772D1 DE 60328772 T DE60328772 T DE 60328772T DE 60328772 T DE60328772 T DE 60328772T DE 60328772 D1 DE60328772 D1 DE 60328772D1
Authority
DE
Germany
Prior art keywords
treatment
progressing
cancer
radiotherapy
hepatoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60328772T
Other languages
German (de)
English (en)
Inventor
John David Rothermel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60328772D1 publication Critical patent/DE60328772D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Silicon Polymers (AREA)
DE60328772T 2002-05-01 2003-04-30 Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen Expired - Lifetime DE60328772D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37706302P 2002-05-01 2002-05-01
PCT/EP2003/004581 WO2003092683A1 (en) 2002-05-01 2003-04-30 Epothilone derivative for the treatment of hepatoma and other cancer diseases

Publications (1)

Publication Number Publication Date
DE60328772D1 true DE60328772D1 (de) 2009-09-24

Family

ID=29401440

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60328772T Expired - Lifetime DE60328772D1 (de) 2002-05-01 2003-04-30 Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen

Country Status (23)

Country Link
US (2) US20050282873A1 (enExample)
EP (1) EP1503756B1 (enExample)
JP (1) JP2005528414A (enExample)
KR (1) KR20040106422A (enExample)
CN (1) CN1649585A (enExample)
AT (1) ATE439130T1 (enExample)
AU (1) AU2003227702B2 (enExample)
BR (1) BR0309711A (enExample)
CA (1) CA2483826C (enExample)
CY (1) CY1109607T1 (enExample)
DE (1) DE60328772D1 (enExample)
DK (1) DK1503756T3 (enExample)
ES (1) ES2330324T3 (enExample)
IL (1) IL164783A (enExample)
MX (1) MXPA04010853A (enExample)
NO (1) NO20045249L (enExample)
NZ (1) NZ536178A (enExample)
PL (1) PL211114B1 (enExample)
PT (1) PT1503756E (enExample)
RU (1) RU2358730C2 (enExample)
SI (1) SI1503756T1 (enExample)
WO (1) WO2003092683A1 (enExample)
ZA (1) ZA200408492B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2358730C2 (ru) * 2002-05-01 2009-06-20 Новартис Аг Производное эпотилона для лечения гепатомы и других раковых заболеваний
BRPI0414043A (pt) * 2003-09-02 2006-10-24 Novartis Ag tratamento de cáncer com epotilonas
US8394365B2 (en) * 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
US20060134214A1 (en) * 2004-11-18 2006-06-22 Ismat Ullah Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
EP2029156A4 (en) 2006-05-01 2010-07-21 Univ Southern California COMBINATION THERAPY FOR CANCER TREATMENT
MX2008004267A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 12 horas.
MX2008004268A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 24 horas.
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
CN101747326B (zh) * 2010-01-12 2012-07-25 山东大学 18元大环内酯类埃博霉素化合物及其应用
WO2011146638A1 (en) 2010-05-18 2011-11-24 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
ATE254615T1 (de) * 1999-02-22 2003-12-15 Biotechnolog Forschung Gmbh C-21 modifizierte epothilone
GB9918429D0 (en) * 1999-08-04 1999-10-06 Novartis Ag Organic compounds
RU2358730C2 (ru) * 2002-05-01 2009-06-20 Новартис Аг Производное эпотилона для лечения гепатомы и других раковых заболеваний

Also Published As

Publication number Publication date
IL164783A0 (en) 2005-12-18
CN1649585A (zh) 2005-08-03
RU2358730C2 (ru) 2009-06-20
PL211114B1 (pl) 2012-04-30
AU2003227702B2 (en) 2007-07-26
ES2330324T3 (es) 2009-12-09
CA2483826C (en) 2012-04-17
MXPA04010853A (es) 2005-02-14
US20080161369A1 (en) 2008-07-03
RU2004135307A (ru) 2005-09-10
NZ536178A (en) 2007-10-26
EP1503756B1 (en) 2009-08-12
IL164783A (en) 2011-08-31
PL371727A1 (en) 2005-06-27
DK1503756T3 (da) 2009-11-16
WO2003092683A1 (en) 2003-11-13
NO20045249L (no) 2005-01-26
AU2003227702A1 (en) 2003-11-17
HK1073601A1 (en) 2005-10-14
SI1503756T1 (sl) 2010-01-29
CA2483826A1 (en) 2003-11-13
ZA200408492B (en) 2006-09-27
JP2005528414A (ja) 2005-09-22
US20050282873A1 (en) 2005-12-22
CY1109607T1 (el) 2014-08-13
ATE439130T1 (de) 2009-08-15
PT1503756E (pt) 2009-10-28
BR0309711A (pt) 2005-02-09
EP1503756A1 (en) 2005-02-09
KR20040106422A (ko) 2004-12-17

Similar Documents

Publication Publication Date Title
CY1109607T1 (el) Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
PH12019502586A1 (en) N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
RU2012140185A (ru) Ингибирование ангиогенеза
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
DE60118889D1 (de) Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
EA201170344A1 (ru) Азаиндольные ингибиторы iap
ATE424208T1 (de) Proteinkinaseinhibitoren
ATE461713T1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
ATE419249T1 (de) Inhibitoren von mitotischem kinesin
DE50211672D1 (de) Urokinase-inhibitoren
ATE406375T1 (de) Antitumor wirksame 2-substituierte d-homoestra-1, 3,5(10)-trien-3-yl sulfamate
ATE400268T1 (de) Bisindolylmaleimid zur behandlung von prostatakrebs und akt-vermittelten erkrankungen
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
EP1663318A4 (en) RADIO-ISOTOPE CHITOSAN COMPLEX FOR THE TREATMENT OF PROSTATE CANCER
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE431348T1 (de) Thiaepothilone zur behandlung von krebserkrankungen
DE502004008294D1 (de) Neue makrocyclen zur behandlung von krebserkrankungen
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN